glenmark

Glenmark Standalone March 2019 Net Sales at Rs 1,587.28 crore, down 4.82% Y-o-Y

Glenmark Consolidated March 2019 Net Sales at Rs 2,563.47 crore, up 12.44% Y-o-Y

Indian pharma majors deny allegations of price fixing in US

The companies have been accused of violating antitrust laws by fixing prices and allocating customers.

Glenmark launches cheaper SGLT2 inhibitor class of anti-diabetes drug in India

The drug, generically called as Remogliflozin etabonate, is used in the treatment of type-2 diabetes mellitus in adults.

Glenmark Consolidated December 2018 Net Sales at Rs 2,555.05 crore, up 15.95% Y-o-Y

Glenmark Standalone December 2018 Net Sales at Rs 1,632.04 crore, up 4.85% Y-o-Y

Glenmark Q3 PAT seen up 96.7% YoY to Rs. 206.5 cr: Sharekhan

Net Sales are expected to increase by 13.2 percent Y-o-Y (down 3.4 percent Q-o-Q) to Rs. 2,494 crore, according to Sharekhan.

Glenmark Q3 PAT seen up 121.5% YoY to Rs. 232 cr: ICICI Direct

Net Sales are expected to increase by 14.4 percent Y-o-Y (down 2.3 percent Q-o-Q) to Rs. 2,521 crore, according to ICICI Direct.

Buy Glenmark; target of Rs 790: HDFC Securities

HDFC Securities is bullish on Glenmark has recommended buy rating on the stock with a target price of Rs 790 in its research report dated November 15, 2018.

Glenmark Standalone September 2018 Net Sales at Rs 1,679.72 crore, up 1.2% Q-o-Q

Glenmark Consolidated September 2018 Net Sales at Rs 2,581.33 crore, Up 14.39% Q-o-Q.

Glenmark Q2 PAT may dip 22% YoY to Rs. 167 cr: Sharekhan

Net Sales are expected to increase by 5.1 percent Y-o-Y (up 9.5 percent Q-o-Q) to Rs. 2,372.4 crore, according to Sharekhan.

Glenmark Q2 PAT seen up 1.7% YoY to Rs. 217.8 cr: ICICI Direct

Net Sales are expected to increase by 12.6 percent Y-o-Y (up 17.3 percent Q-o-Q) to Rs. 2,540 crore, according to ICICI Direct.

PE player True North to hawk Glenmark's ortho, pain drugs under new entity

The new entity named as 'Integrace Private Ltd' will market the product portfolio in India and Nepal, Glenmark said in a statement

Glenmark banks on complex and differentiated products to beat US pricing pressure

"Pricing pressure (in US) continues. I don't think we are going to see any moderation," Glenn Saldanha, Chairman and Managing Director of Glenmark, told Moneycontrol.

Buy Glenmark; target of Rs 691: HDFC Securities

HDFC Securities is bullish on Glenmark has recommended buy rating on the stock with a target price of Rs 691 in its research report dated August 16, 2018.

Glenmark signs licence deal with Harbour BioMed to commercialise cancer antibody in Greater China

Harbour BioMed will lead the clinical development and commercialisation of GBR 1302, with the option to manufacture GBR 1302 for the Greater China market.

Buy Glenmark; target of Rs 710: HDFC Securities

HDFC Securities is bullish on Glenmark has recommended buy rating on the stock with a target price of Rs 710 in its research report dated May 31, 2018.

Glenmark gets USFDA nod for contraceptive drugs

"Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Hailey 1.5/30 (Norethindrone Acetate and Ethinyl Estradiol tablets USP, 1.5 mg/30 mcg) and Hailey Fe 1.5/30 (Norethindrone Acetate and Ethinyl Estradiol tablets, USP and Ferrous Fumarate tablets, 1.5 mg/30 mcg)," the company said in a BSE filing.

Glenmark Q4 profit drops 17.5% YoY to Rs 152 crore, but beats estimates

The revenues for Q4 declined 7.2 percent YoY to Rs 2,280 crore from Rs 2,457.1 crore last year.

DCGI seeks response from Glenmark on clinical trial deficiencies by May 12

Indian drug regulator found deficiencies in clinical trial protocols including an alleged falsification of patient enrollment data at Malpani Multispecialty Hospital in Jaipur, Rajasthan – in connection to a clinical trial of company’s osteoarthritis pain drug (GRC 27864) tested on patients as part of phase-2 trial.

Glenmark enters licensing pact with Helsinn to distribute its chemo-induced nausea drug

The licensing agreement with Glenmark for Akynzeo marks the Swiss drugmaker's first such agreement in India

Buy Glenmark; target of Rs 787: Dolat Capital

Dolat Capital is bullish on Glenmark has recommended buy rating on the stock with a target price of Rs 787 in its research report dated February 12, 2018.

Glenmark net profit drops 4% in Q2 to Rs 214 crore

While the net profit beat analyst estimates, revenues were in line with expectations. A CNBC-TV18 poll of analysts estimated the net profit to be at Rs 180.4 crore and revenues at Rs 2264.3 crore.

DRL, Sun Pharma, Glenmark among 18 under US lens on price fixing complaint

An official statement issued by Attorney General (AG) of Washington State, Bob Ferguson, yesterday said AGs of 45 other states, along with him, approached a federal court seeking to expand the pending complaint, increase the number of drug companies under probe to 18 from 6 and the number of affected drugs to 15 from 2.